Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Reporting Period: Quarterly Report on Form 10-Q for the period ended December 31, 2007.
Business Stage: Clinical development stage company focused on regenerative medicine using autologous cell products (Tissue Repair Cell or TRC technology). The company has not yet generated significant product sales and relies on grants and equity financing.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2007 | Six Months Ended Dec 31, 2007 | Balance Sheet (Dec 31, 2007) |
|---|---|---|---|
| Total Revenues | $84,000 | $171,000 | N/A |
| Net Loss | $(5,172,000) | $(10,222,000) | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.04) | $(0.08) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $16,259,000 |
| Short-term Investments | N/A | N/A | $14,930,000 |
| Total Current Assets | N/A | N/A | $33,431,000 |
| Total Current Liabilities | N/A | N/A | $2,156,000 |
| Long-term Debt | N/A | N/A | $1,011,000 |
| Accumulated Deficit | N/A | N/A | $(169,966,000) |
Revenue Composition: Revenues consist primarily of grants (79% of six-month total) and minimal product sales/rentals ($36,000 for six months).
Operating Expenses: Research and Development (R&D) expenses were $3.9 million for the quarter and $7.8 million for the six months. Selling, General, and Administrative (SG&A) expenses were $1.7 million for the quarter and $3.3 million for the six months.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased to $84,000 for the quarter ended Dec 31, 2007, from $158,000 in the same period in 2006. This was driven by a decrease in grant revenues from the National Institutes of Health.
- Expense Increase: Total costs and expenses increased to $5.6 million for the quarter (from $4.9 million) and $11.1 million for the six months (from $9.6 million). R&D expenses rose significantly due to expanded clinical trial activities in the U.S. and EU.
- SG&A Reduction: SG&A expenses decreased compared to the prior year, primarily due to the absence of one-time non-cash charges related to the former CEO's stock options recorded in the prior year.
- Net Loss Increase: Net loss increased to $5.2 million for the quarter and $10.2 million for the six months, reflecting higher operating costs.
- Liquidity Improvement: Cash and cash equivalents increased to $16.3 million at period end, supported by a registered direct offering of common stock and warrants that generated net proceeds of approximately $12.4 million.
Guidance, Outlook, Risks, and Unusual Items
- Cash Burn and Funding Needs: Management expects monthly cash utilization to average approximately $1.8 million for the remainder of fiscal year 2008. The company does not expect to generate positive cash flows for at least several years and will require additional funding to complete clinical trials and commercialization.
- Nasdaq Delisting Risk: On December 20, 2007, the company received a deficiency letter from Nasdaq for failing to maintain a minimum closing bid price of $1.00 for 30 consecutive days. The company has an 180-day compliance period (until June 17, 2008) to regain compliance or risk delisting.
- Clinical Trial Progress:
- Vascular: RESTORE-CLI Phase IIb trial enrolling patients in the U.S.; positive interim data reported from a German trial.
- Bone: ON-CORE Phase III trial enrolling patients in the U.S. for osteonecrosis; positive final results reported for non-union fractures.
- Cardiac: Compassionate-use treatments initiated in Europe for dilated cardiomyopathy.
- Stock-Based Compensation: Significant non-cash expenses related to stock options. No expense was recorded for performance-based options as vesting conditions were not deemed probable.
- Regulatory Risks: Success depends on obtaining FDA and EU regulatory approvals. Changes in regulatory classification could delay or prevent marketing.
Investor Verification Checklist
- Capital Adequacy: Verify if the company has secured additional financing beyond the $12.4 million raised in the period to cover the projected $1.8 million monthly burn rate.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement to avoid delisting by June 17, 2008.
- Clinical Trial Enrollment: Confirm patient enrollment rates for the RESTORE-CLI and ON-CORE trials, as delays could increase costs and delay revenue generation.
- Regulatory Status: Track FDA and EU regulatory decisions regarding the classification of TRC-based products and approval of clinical protocols.
- Dilution Risk: Assess the impact of potential future equity issuances required to fund operations, given the company's history of financing through stock sales.